Publications

Publications

Scientific contributions highlighting the impact of Diatech Pharmacogenetics technologies in diagnostics.

Filter

All years 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2008
All product lines Easy Easy PGX Helix Microsatelliti Myriapod Myriapod NGS Realquant Response
  • Myriapod

RNA sequencing reveals PNN and KCNQ1OT1as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy

  • Myriapod

From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC

  • Myriapod

Phase 2 study of tivantinib and cetuximab in KRAS wild-type metastatic colorectal cancer patients with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR/MET dual inhibition

  • Microsatelliti, Myriapod

Matteo Fassan et. al, miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis

  • Easy, Myriapod

Nora Sahnane et. al, Comprehensive analysis of HPV infection, EGFR exon 20 mutations and LINE1 hypomethylation as risk factors for malignant transformation of sinonasal inverted papilloma to squamous cell carcinoma

  • Myriapod

Simona Osella Abate et. al, ALK expression favorably impacts the prognosis of NRAS?mutated metastatic melanomas

  • Myriapod

Stefano Pizzolitto et. al, An unusual case of squamous cell carcinoma of the right colon

  • Myriapod

Imerio Angriman et. al, Effects of immune suppression for transplantation on inflammatory colorectal cancer progression

  • Myriapod

Iván Prieto Potin et. al, Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer

  • Myriapod

Luca Reggiani Bonetti et. al, Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer

Your next step starts here. Fill out the form and talk to us

Let's talk